HOME >> BIOLOGY >> NEWS
Scientist honored for studies of genetic influence on chemotherapy, tumor development

ary cause of resistance to apoptosis in cancer cells, Dr. Lowe has shown that the p53 pathway, including proteins such as p19, Arf, Apaf-1 and capase-9, is responsible for inducing apoptosis in cancer cells in response to chemotherapeutic agents."

NFCR science director Sujuan Ba, Ph.D., added, "Chemotherapy today remains the most used technique for battling cancer and Dr. Lowe is on the front lines of this research. His research in the genetic understanding of cellular life and death is exactly what will allow us to continue to make gains in how cancer is treated, diagnosed and eventually defeated."

Lowe's early research focused on the relationship between p53 gene mutation status and the resistance of cancer cells to radiation and chemotherapy. Currently, he and his colleagues are beginning to assemble the genetic components of the p53 pathway into a tumor suppressor network, with the intent of discovering how oncogenes or DNA damaging agents signal p53, how p53 responds biologically, and the factors that influence whether p53 induces a cell-cycle checkpoint, senescence or apoptosis. He has also employed mouse models for human cancer, such as the Em-myc oncogene-induced lymphoma in the mouse, to study cancer progression and the relationship between cancer mutations and the response of genetically defined tumors to therapy.

Previously, Lowe was honored by the AACR with its 2001 Award for Outstanding Achievement in Cancer Research, for his work on the p53 tumor suppressor gene; and, in 1993, he received an AACR Scholar-in-Training Award on the strength of his cell death research.

Tamara and Franklin Salisbury, Sr., founded the NFCR in 1973. Franklin, an attorney and entrepreneur, and Tamara, a research chemist at the National Cancer Institute and a project officer in the chemistry branch of the Office of Naval Research, were inspired by the work of Albert Szent-Gyorgyi, who received the Nobel Prize for hi
'"/>

Contact: Elizabeth Tait
tait@aacr.org
215-440-9300
American Association for Cancer Research
24-Jun-2004


Page: 1 2 3

Related biology news :

1. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
2. Scientists sequence genome of kind of organism central to biospheres carbon cycle
3. Scientists find nanowires capable of detecting individual viruses
4. Scientists discover potential new way to control drug-resistant bacteria
5. Scientists explore genome of methane-breathing microbe
6. Scientists decipher genetic code of biothreat pathogen
7. Stuck on you: Scientists lay bare secrets of bacterial attachment proteins
8. Scientists discover proteins involved in spread of HIV-1 infection
9. Scientists fear new Ebola outbreak may explain sudden gorilla disappearance
10. Scientists reinvent DNA as template to produce organic molecules
11. Scientists visualise cellular handmaiden that restores shape to proteins

Post Your Comments:
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: